---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-008965"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2023-02-07T23:59:59+00:00"
generated_at: "2026-06-19T23:03:18.353932+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Unicycive receives Nasdaq delisting notice for bid price non-compliance; equity below $5M

## Summary
- On Feb 1, 2023, Nasdaq notified Unicycive (UNCY) that it failed to regain minimum bid price compliance by Jan 30 deadline.
- Company not eligible for second 180-day grace period because stockholders' equity of $4.626M was below $5M initial listing requirement.
- Unicycive requested a hearing before the Nasdaq Hearings Panel, scheduled for March 23, 2023, to stay delisting.
- If Panel grants extension, company may have until August 8, 2023 to cure bid-price deficiency.
- Common stock continues trading on Nasdaq under symbol UNCY pending hearing outcome.

## SEC filing metadata
- accession: 0001213900-23-008965
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2023-02-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390023008965/0001213900-23-008965-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390023008965/ea172745-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-008965
- JSON: https://secwatch.observer/filing/0001213900-23-008965.json
- Plain text: https://secwatch.observer/filing/0001213900-23-008965.txt

## Key facts
- Listing & Compliance Notices
  Unicycive Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: stockholders equity
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: February 1, 2023, Nasdaq notified the Company that it had not regained compliance with the Rule and was not eligible for a second 180 day period since the Company did not comply with the minimum $5,000,000 stockholders’ equity initial listing requirement for The Nasdaq Capital Market. In that regard, the Company’s stockholders’ equity as of September 30, 2022 was reported to be approximately $4,626,000, in the Company’s Form 10-Q filed on November 14, 2022. Further, the Staff informed the Company that its common stock would be subject to delisting from The Nasdaq Capital Market unless the Comp
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023008965/0001213900-23-008965-index.htm
- Listing & Compliance Notices
  Unicycive Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: February 1, 2023, Nasdaq notified the Company that it had not regained compliance with the Rule and was not eligible for a second 180 day period since the Company did not comply with the minimum $5,000,000 stockholders’ equity initial listing requirement for The Nasdaq Capital Market. In that regard, the Company’s stockholders’ equity as of September 30, 2022 was reported to be approximately $4,626,000, in the Company’s Form 10-Q filed on November 14, 2022. Further, the Staff informed the Company that its common stock would be subject to delisting from The Nasdaq Capital Market unless the Comp
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023008965/0001213900-23-008965-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.